Irish medical device company Nua Surgical has secured €6.5 million in Series A funding led by EQT Life Sciences, with participation from Kidron Capital, Texas Medical Center Venture Fund, and existing investors including Enterprise Ireland.
The funding will support regulatory clearance and early commercialization of SteriCISION, the first self-retaining retractor specifically designed for Caesarean section surgeries. With over 30 million C-sections performed globally each year, the device aims to provide fast, adjustable, and safe retraction during surgery.
“Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercializing SteriCISION,” said Barry McCann, CEO of Nua Surgical.
“Nua Surgical’s SteriCISION C-Section Retractor has the potential to significantly enhance outcomes for mothers undergoing C-section procedures,” said Anne Portwich, Partner at EQT. “We are excited to support the company’s journey towards market entry. This innovative device has the potential to improve the quality of care and reduce healthcare costs, making it a perfect fit for our EQT Health Economics strategy.”
The company plans to use the proceeds for team expansion, establishing manufacturing in Ireland, and pursuing FDA clearance. Following the investment, Anne Portwich and Anula Jayasuriya will join Nua Surgical’s Board of Directors, with Gabrielle Guttman and Prashanthi Ramesh serving as Board Observers.
